Tetrous, Inc.

Tetrous, Inc. develops biologic solutions for orthopedic bone-to-tendon healing, specifically addressing enthesis failure in rotator cuff and other tendon repairs. The company manufactures EnFix®, a demineralized bone fiber-based device designed to optimize tissue remodeling at the bone-tendon interface (enthesis). EnFix® employs proprietary Bone Textile™ technology to produce long, strong fibers that promote cell wicking, adhesion, and proliferation, and FormLok™ technology for shape retention in surgical environments. The product is available in multiple configurations (TAC-T, TAC-O, and RC variants) for use with suture anchors in arthroscopic procedures. Tetrous addresses a significant clinical need: more than 500,000 rotator cuff repairs are performed annually in the US at a $3 billion market, with structural failure rates ranging from 20–70%, particularly in larger tears. The company's technology has demonstrated osteoconductivity and osteoinductivity in clinical studies and surgical applications. Tetrous received the 2024 AOSSM (American Orthopaedic Society for Sports Medicine) ACE Award, validating its clinical impact in sports medicine and orthopedic surgery. The device integrates into existing surgical workflows and is positioned as an augmentation approach that addresses healing at the tendon-to-bone interface rather than overlay/patch reinforcement strategies.